Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 1.00 |
| ▸ | JAK3 | P52333 | 4/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16764045 | 1.00 | BTK (1.00) | BTKJAK3MAP4K4RETEGFR | |
| SCHEMBL16802151 | 0.86 | BTK (0.75) | BTKJAK3EGFRLCKCKS1B | |
| SCHEMBL22346809 | 0.85 | BTK (0.74) | BTKJAK3EGFRLCK | |
| SCHEMBL16764041 | 0.85 | BTK (0.74) | BTKJAK3EGFRLCK | |
| SCHEMBL18283881 | 0.85 | JAK3 (0.74) | BTKJAK3MAP4K4RETEGFR | |
| SCHEMBL16764457 | 0.83 | BTK (0.72) | BTKJAK3EGFRLCK | |
| SCHEMBL16764458 | 0.83 | BTK (0.72) | BTKJAK3EGFRLCK | |
| SCHEMBL18283568 | 0.83 | JAK3 (0.71) | BTKJAK3MAP4K4RETCKS1B | |
| SCHEMBL18283636 | 0.82 | BTK (0.70) | BTKJAK3MAP4K4RETEGFR | |
| SCHEMBL22359017 | 0.82 | JAK3 (0.69) | BTKJAK3MAP4K4RETEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| CN-115003304-A | Bifunctional compounds for the degradation of BTK via the ubiquitin proteasome pathway | 纽力克斯治疗公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220143195-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2020167518-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885JAK3 53/4885MAP4K4 609/4885 |
| US-20220143195-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | BTK 3/4885JAK3 623/4885MAP4K4 2142/4885 |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885JAK3 64/4885MAP4K4 568/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | BTK 1/4885JAK3 553/4885MAP4K4 2078/4885 |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885JAK3 60/4885MAP4K4 603/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | BTK 1/4885JAK3 553/4885MAP4K4 2078/4885 |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885JAK3 60/4885MAP4K4 603/4885 |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885JAK3 60/4885MAP4K4 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.